US Patent

US11839689 — Formulations of enzalutamide

Formulation · Assigned to Astellas Pharma Inc · Expires 2033-09-11 · 7y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of enzalutamide, a drug used to treat hyperproliferative disorders.

USPTO Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US11839689
Jurisdiction
US
Classification
Formulation
Expires
2033-09-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.